BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 18571698)

  • 1. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.
    Harder S; Parisius J; Picard-Willems B
    Thromb Res; 2008; 123(2):396-403. PubMed ID: 18571698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.
    Harenberg J; Giese C; Hagedorn A; Traeger I; Fenyvesi T
    Semin Thromb Hemost; 2007 Jul; 33(5):503-7. PubMed ID: 17629847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.
    Kluft C; Meijer P; Kret R; Burggraaf J
    Int J Lab Hematol; 2013 Aug; 35(4):379-84. PubMed ID: 23151091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A; Peetz D; Haas S; Spannagl M; Rudin K; Wilmer M
    Am J Clin Pathol; 2008 Sep; 130(3):446-54. PubMed ID: 18701419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
    J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.
    Rezaie AR
    Thromb Res; 2007; 119(4):481-8. PubMed ID: 16515805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement.
    Virtanen L; Salmela B; Leinonen J; Lemponen M; Huhtala J; Joutsi-Korhonen L; Lassila R
    Blood Coagul Fibrinolysis; 2014 Sep; 25(6):597-603. PubMed ID: 24732174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats.
    Konishi N; Hiroe K; Kawamura M
    J Cardiovasc Pharmacol; 2011 Feb; 57(2):201-6. PubMed ID: 21052010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
    Schaden E; Schober A; Hacker S; Spiss C; Chiari A; Kozek-Langenecker S
    Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
    Honda Y; Kamisato C; Morishima Y
    Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.
    Hérault JP; Bernat A; Pflieger AM; Lormeau JC; Herbert JM
    J Pharmacol Exp Ther; 1997 Oct; 283(1):16-22. PubMed ID: 9336303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
    Banke IJ; Arlt MJ; Mueller MM; Sperl S; Stemberger A; Stürzebecher J; Amirkhosravi A; Moroder L; Krüger A
    Thromb Haemost; 2005 Nov; 94(5):1084-93. PubMed ID: 16363253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reduced anticoagulant effect of fondaparinux at low antithrombin levels.
    Dempfle CE; Eichner J; Suvajac N; Ahmad-Nejad P; Neumaier M; Borggrefe M
    Anesth Analg; 2009 Sep; 109(3):712-6. PubMed ID: 19690236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    Graff J; von Hentig N; Misselwitz F; Kubitza D; Becka M; Breddin HK; Harder S
    J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.